A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab Monotherapy in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 14 Dec 2018
At a glance
- Drugs Tralokinumab (Primary)
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Acronyms ECZTRA 1
- Sponsors LEO Pharma
- 05 Dec 2018 Planned End Date changed from 1 Nov 2019 to 1 Oct 2019.
- 05 Oct 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Mar 2019.
- 16 Jul 2018 Planned End Date changed from 8 Jun 2020 to 1 Nov 2019.